Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across. Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of. Cardiff Oncology Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatment for cancer patients. Cardiff Oncology is a clinical-stage company with the mission of developing new treatment options for cancer patients. #Oncology #ColorectalCancer. Cardiff Oncology, Inc. (avtoelektrik-chrp.ru): Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Cardiff Oncology, Inc. | Nasdaq.
Cardiff Oncology to Report Fourth Quarter and Full Year Results and Provide Business Update - Management will hold a conference call on Thursday. Last Funding Type Post-IPO Equity; Also Known As TrovaGene; Legal Name Cardiff Oncology, Inc. Stock Symbol NASDAQ:CRDF; Company Type For Profit. Contact Email. Cardiff Oncology is a clinical-stage biotechnology company, headquartered in San Diego, CA, leveraging PLK1 inhibition, a well-validated oncology drug. Cardiff Oncology to Report Fourth Quarter and Full Year Results and Provide Business Update - Management will hold a conference call on Thursday. Cardiff Oncology, Inc. (CRDF) has a Smart Score of 3 based on an analysis of 8 unique data sets, including Analyst Recommendations, Crowd Wisdom. Cardiff Oncology Inc company profile analysis with the premuim data - Globaldata. Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of. Cardiff Oncology to Present at Upcoming Investor Conferences in May. SAN DIEGO, May 13, (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a. Cardiff Oncology, Inc.: Company profile, business summary, shareholders, managers, financial ratings, industry, sector and market information | Nasdaq: CRDF. Discover real-time Cardiff Oncology, Inc. Common Stock (CRDF) stock prices, quotes, historical data, news, and Insights for informed trading and investment. Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types.
Cardiff Oncology, Inc. is a biotechnology firm based in the United States, specializing in the development of treatment options for cancer patients through. Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is. Cardiff Oncology, Inc. operates as a biotech company. The Company develops therapies and treatments for solid tumor and hematologic cancers. Cardiff Oncology Inc. · Industry Pharmaceuticals · Sector Health Care/Life Sciences · Fiscal Year-end 12/ · Revenue $K · Net Income -$M · Sales. Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops Cardiff Oncology, Inc. was incorporated in and is headquartered in. Key statistics. On Friday, Cardiff Oncology Inc (CRDF:NAQ) closed at , % above the 52 week low of set on Nov 10, Data delayed at least Cardiff Oncology Inc. ; Market Value, $M ; Shares Outstanding, M ; EPS (TTM), -$ ; P/E Ratio (TTM), N/A ; Dividend Yield, N/A. Get the latest Cardiff Oncology Inc (CRDF) real-time quote, historical performance, charts, and other financial information to help you make more informed. Research outputs, collaborations and relationships for Cardiff Oncology, Inc.
Cardiff Oncology (Nasdaq: CRDF), a clinical-stage biotechnology company focusing on PLK1 inhibition for cancer therapies, has announced its plan to release. Cardiff Oncology, Inc. is a clinical-stage biotechnology company. It is leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel. Second quarter earnings: Revenues exceed analysts expectations while EPS lags behind. Aug 09 ; Cardiff Oncology, Inc. to Report Q2, Results on Aug Article 'Count' and 'Share' for Cardiff Oncology, Inc. based on listed parameters only. According to the parameters selected above, there are no articles from. Company profile for Cardiff Oncology Inc. including key executives, insider trading, ownership, revenue and average growth rates.
Speedrun of Cardiff Oncology (CRDF)
About Cardiff Oncology, Inc. Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to. Get Cardiff Oncology Inc. (CRDF) share price today, stock analysis, stock rating, price valuation, performance, fundamentals, market cap, shareholding. Cardiff Oncology Inc share price live: CRDF Live stock price with charts, valuation, financials, price target & latest insights. Cardiff Oncology Inc. balance sheet, income statement, cash flow, earnings & estimates, ratio and margins. View CRDF financial statements in full. CRDF - Cardiff Oncology, Inc. Stock - Stock Price, Institutional Ownership, Shareholders (NasdaqCM).